Newsletter summary

On the evening of April 29th, Haizheng Pharmaceutical (600267) released its annual report of 2023 and quarterly report of 2024. The report shows that Haizheng Pharmaceutical achieved an operating income of 10.373 billion yuan in 2023, and the gross profit margin of its main business was 40.87.

Text of news flash

On the evening of April 29th, Haizheng Pharmaceutical (600267) released its annual report of 2023 and quarterly report of 2024. According to the report, Haizheng Pharmaceutical achieved an operating income of 10.373 billion yuan in 2023; the gross profit margin of its main business was 40.87%; and the net operating cash flow was 1.503 billion yuan. The company said that as a research, production and marketing of the whole value chain, API and preparation integration, multi-regional developmentNanoblockcrashbandicootIn the future, comprehensive pharmaceutical enterprises will focus on the development of chemical, biological, animal, traditional Chinese medicine and pharmaceutical commerce and other industries, speed up the layout of emerging markets such as large health industries and health aesthetics, and continue to add new impetus for development and devise a new layout of research and development. In 2023, in the face of industry changes and internal adjustment, Haizheng Pharmaceutical Co., Ltd. continued to promote the company's internal adjustment and improvement, with the management "veteran return", internal management to a new level. In October 2023, Haizheng Pharmaceutical Company appointed Xiao Weihong as its president. It is understood that Xiao Weihong has held important positions in a number of pharmaceutical companies in the industry, including Hanhui Pharmaceutical, a subsidiary of Haizheng Pharmaceutical, and is more familiar with the internal situation of Haizheng Pharmaceutical Industry. Under the comb of the new management of Haizheng Pharmaceutical Co., Ltd., the production, research and development, sales and other work of the company are carried out in a normal and orderly manner. According to the first quarterly report in 2024, Haizheng Pharmaceutical achieved an operating income of 2.727 billion yuan, a net profit of 249 million yuan, an increase of 6.99% over the same period last year, and a net operating cash flow of 315 million yuan, an increase of 3.49% over the same period last year. At the beginning of 2024, Haizheng Pharmaceutical Company successfully passed the review and evaluation of the national technological innovation demonstration enterprise in 2023, which once again proved that the company's technological innovation capability and achievements in the pharmaceutical industry have been highly recognized by the country. At the same time, the layout of the company in the industrial side has also accelerated the pace. In January this year, the company and Sinopharm signed a strategic cooperation agreement on retail projects, and the two sides will carry out in-depth cooperation in medical and retail channels to maximize synergy through the integration of their superior resources. to bring patients a more personalized, more convenient and more efficient drug purchase experience; in the same month, the company also signed a "Strategic Cooperation Framework Agreement" with Baicheng Pharmaceutical to carry out multi-faceted cooperation of the whole industry chain. In March, the company and Aaron, the Nobel laureate in chemistryNanoblockcrashbandicoot? Professor Chehanovo signed an intention agreement on "Global Strategic Cooperation in creating New drugs", and the two sides will jointly develop the world's first new drugs. On April 29, Haizheng Pharmaceutical Company formally became a shareholder of Vanoxi, an original new drug research and development company, through capital increase. The two sides will carry out all-round strategic cooperation in innovative drug research and development. The industry expects that the new management is expected to lead Haizheng Pharmaceutical Industry into a new cycle of development. According to reports, Haizheng Pharmaceutical will continue to carry out accurate and efficient research and development and strengthen internal control management while steadily promoting pharmaceutical preparation business, API business, animal medicine business, and emerging business along the strategic path of "business orientation, steady development, profit first, and reshaping status". To achieve the sustained and healthy development of the company. (Li Ping) proofread: Zhu Tianting